Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis

Trial Profile

A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Axial spondyloarthritis
  • Focus Therapeutic Use
  • Acronyms SKIPPAIN
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 09 Nov 2021 Results of post hoc analysis assessing association of the HLA-B27 subtypes and efficacy of secukinumab presented at the ACR Convergence 2021
    • 06 Jun 2020 Primary endpoint (Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8) has been met according to the results presented at the 21st Annual Congress of the European League Against Rheumatism
    • 06 Jun 2020 Results from the 24-Week study assessing efficacy and safety of secukinumab (SEC) in reducing spinal pain in patients with axSpA who had an inadequate response to NSAIDs presented at the 21st Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top